As shown in Table 1, most approved TCEs are indicated for hematological malignancies and have shown their ability to target CD19 in B-cell precursor acute lymphoblastic leukemia (B-ALL), CD20 in non-Hodgkin lymphoma, B-cell maturation antigen (BCMA), and G protein–coupled receptor GPRC5D in multiple myeloma. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.